================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934
FILING NO. 2 FOR THE MONTH OF NOVEMBER, 2001
Visible Genetics Inc.
------------------------------------------------------
(Exact name of Registrant)
700 Bay Street, Suite 1000, Toronto ON, Canada M5G 1Z6
------------------------------------------------------
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F
Form 20-F |X| Form 40-F ___
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ___ No |X|
================================================================================
VISIBLE GENETICS INC.
On November 21, 2001, we reported that David A. Galloway, who has been
President and Chief Executive Officer of Torstar Corporation since 1988, has
joined our Board of Directors, replacing Robert Prichard. Dr. Prichard, who is
Galloway's designated successor at Torstar, has stepped down because of time
commitments of his new job.
Torstar is a leading Canadian media company. Prior to joining Torstar, Mr.
Galloway was one of the founding partners of Canada Consulting Group, a leading
strategic management consulting group which was subsequently sold to Boston
Consulting Group in 1992.
Born in Toronto, Mr. Galloway earned a Bachelor of Arts degree in Political
Science and Economics from the University of Toronto, and a Masters in Business
Administration from Harvard Graduate School of Business. Mr. Galloway is
currently on the Board of Trustees of The Hospital For Sick Children. In
addition, he currently is a director of the Bank of Montreal and Corel
Corporation.
This Form 6-K contains forward-looking statements within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are subject to risks, uncertainties and
other factors which may cause our results to differ materially from
expectations. These include risks relating to the ability to obtain market
acceptance of genotyping and our products, delays in, or the refusal of,
insurance companies and other third-party payors to reimburse us for our
products, delays in product development, our ability to acquire and protect
intellectual property important to our business through patents, licenses or
other arrangements, claims that our intellectual property may interfere with the
rights of others, ability to obtain regulatory approvals, delays in making the
new Atlanta manufacturing facility operational, and other risks detailed from
time to time in our SEC filings, including our most recent Annual Report on Form
20-F. These forward-looking statements speak only as of the date hereof. We
disclaim any intent or obligation to update these forward-looking statements.
We hereby incorporate by reference this Form 6-K into our Registration
Statements on Form F-3, and into the prospectuses contained therein, (File Nos.
333-67607, 333-68939, 333-91155, 333-94649 and 333-40616) and our outstanding
Registration Statements on Form S-8 and into the reoffer prospectuses contained
therein.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VISIBLE GENETICS INC.
Date: November 21, 2001 By: /s/ THOMAS CLARKE
------------------------------
Name: Thomas Clarke
Title: Chief Financial Officer